Eloxx Pharmaceuticals, Inc.
No enriched coverage for $ELOX in the last 7 days.
No SEC Form 4 filings for $ELOX in the last 30 days.
See all $ELOX insider activity →Eloxx Pharmaceuticals (ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for nonsense mutation Alport syndrome. Topline data is expected mid-2027, with a final readout by year-end 2027. The trial aims to evaluate exaluren's safety and efficacy in 24 patients.
Several biotech stocks hit 52-week highs on August 21, 2026. Eloxx (ELOX) rose 16% to $23.40, reporting a Q2 net loss of $4.5M. argenX (ARGX) reached $1,058.69, with positive trial results for VYVGART. Corcept (CORT) hit $123.44, reporting $256M in Q2 revenue. Boundless Bio (BOLD) reached $3.02, initiating a first-in-human trial. Prelude (PRLD) peaked at $6.38, advancing JAK2V617F in Phase 1 trials.
Eloxx Pharmaceuticals (ELOX) rose 20% after FDA cleared its Phase 2b trial for exaluren. Vogenx (VOGX) gained 14% post-IPO. Arcturus (ARCT) advanced 21% on pipeline updates. Zhengye (ZYBT) +7% after Nasdaq compliance. Greenwich (GLSI) +10% on extended lock-up. HeartSciences (HSCS) +8% after $1M investment. AC Immune (ACIU) +8% on Phase 1 data.
Recent ELOX coverage spans earnings, financial news and market movers.
The dosing milestone initiates the first patient‑level data collection for a rare‑disease program, setting a timeline for mid‑2027 topline data.
Positive trial progress and licensing deal drive short‑term upside.
Positive regulatory clearance and trial initiation suggest near‑term upside.
The capital raise strengthens the balance sheet while the trial initiation may drive future upside; short-term stock may react to loss widening.
New 13G stake disclosure increases visibility into a near-10% holder, potentially affecting perceived control dynamics and future financing or governance expectations.
AlphAI scores every news story that mentions ELOX with an AI model for sentiment and relevance, and aggregates insider trades from Eloxx Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Eloxx Pharmaceuticals (ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for nonsense mutation Alport syndrome. Topline data is expected mid-2027, with a final readout by year-end 2027. The trial aims to evaluate exaluren's safety and efficacy in 24 patients.
2 min readSeveral biotech stocks hit 52-week highs on August 21, 2026. Eloxx (ELOX) rose 16% to $23.40, reporting a Q2 net loss of $4.5M. argenX (ARGX) reached $1,058.69, with positive trial results for VYVGART. Corcept (CORT) hit $123.44, reporting $256M in Q2 revenue. Boundless Bio (BOLD) reached $3.02, initiating a first-in-human trial. Prelude (PRLD) peaked at $6.38, advancing JAK2V617F in Phase 1 trials.
3 min readEloxx Pharmaceuticals (ELOX) rose 20% after FDA cleared its Phase 2b trial for exaluren. Vogenx (VOGX) gained 14% post-IPO. Arcturus (ARCT) advanced 21% on pipeline updates. Zhengye (ZYBT) +7% after Nasdaq compliance. Greenwich (GLSI) +10% on extended lock-up. HeartSciences (HSCS) +8% after $1M investment. AC Immune (ACIU) +8% on Phase 1 data.
3 min readEloxx Pharmaceuticals reported a wider Q2 2026 loss of $4.5M, up from $1.9M a year ago, due to higher R&D and G&A expenses. The company raised $58.3M in a public offering and uplisted to Nasdaq. Eloxx plans to start a Phase 2b trial for exaluren in Q3 2026, with data expected in 2027. The stock is up 18.10% to $21.31.
2 min readEloxx Pharmaceuticals, Inc. reported Schedule 13G filings showing Samsara BioCapital and its affiliates each hold 201,793 shares, about 5.0% of Eloxx common stock. Dr. Srinivas Akkaraju reports 403,586 shares, 9.99%, based on 4,036,314 shares outstanding as of June 10, 2026. Pre-funded warrants include a 9.99% beneficial ownership blocker.
3 min readEloxx Pharmaceuticals (Nasdaq: ELOX) reported Q2 2026 results and a business update. It completed a $66.0 million underwritten public offering and uplisted to Nasdaq (symbol ELOX). Cash was $62.0 million at June 30, 2026. Phase 2b exaluren in nonsense mutation Alport syndrome is expected to start Q3 2026; ADPKD trial planned for 2027. Net loss was $4.5 million.
6 min readEloxx Pharmaceuticals, Inc. (ELOX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update • Completed underwritten public offering with gross proceeds of $66.0 million and uplisting to the Nasdaq Capital Market, significantly strengthening the Company’s balanc
6 min readBiotech shares hit 52-week highs on Aug. 3-4, 2026, led by catalysts including upcoming quarterly reports and clinical-trial updates. AngioDynamics (ANGO) reached $15.41, citing FDA clearance for its RELIEF study and FY2026 net sales of $320.2 million. Anika (ANIK) hit $21.11 after Q2 revenue rose to $32.6 million. Pulse (PLSE) rose to $38.29 ahead of Aug. 6 results; Eloxx (ELOX) and Yarrow (YARW) also reached highs.
7 min read
